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Abstract 
Aminaphtone (AMNA), a naphtohydrochinone used in the treatment of capillary 
disorders, may affect oedema in chronic venous insufficiency (CVI). Aim of study is to 
investigate the effect of AMNA on vascular endothelial permeability in vitro and its 
effects on three-dimensional capillary-like structures formed by Human Umbilical Vein 
Endothelial Cells (HUVECs).  
HUVECs were treated with 50 ng/ml VEGF for 2h and AMNA for 6h. Permeability 
assay, VE-cadherin expression and Matrigel assay were performed.  
VEGF-induced permeability was significantly decreased by AMNA in a range 
concentration of 1-20 µg/ml. AMNA restored VE-cadherin expression. Finally, 6h pre-
treatment with AMNA significantly preserved capillary-like structures formed by 
HUVECs on Matrigel up to 48 h compared to untreated cells.  
AMNA significantly protects endothelium permeability and stabilises endothelial cells 
organised in capillary-like structures, modulating VE-cadherin expression. These data 
might explain the clinical benefict of AMNA on CVI.  
 
Keywords. Aminaphtone, Human Umbilical Vein Endothelial Cells, permeability, 
chronic venous insufficiency, capillary fragility, VE-cadherin  
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1. Introduction 
Vascular permeability is an extremely complicated process that is affected by many 
different variables 
1
. A rapid increase in vascular permeability occurs when the 
microvasculature is exposed to any of a number of vascular permeabilising factors, e.g. 
vascular endothelial growth factor A (VEGF-A), histamine, platelet activating factor 
1
. 
This process has been implicated in many pathological conditions such as angiogenesis, 
ischaemic heart disease, acute and chronic inflammation, trauma, wound-healing 
2
.  
The dynamic equilibrium between cell adhesion and cytoskeleton contraction plays an 
important role in maintaining the normal function of endothelial permeability 
3
. The 
intercellular junctions of endothelial cells have an important barrier function regulating 
the permeability to small molecules and even to cells 
4
. Several families of cytoadhesive 
proteins, such as the selectins, members of the immunoglobulin (Ig) superfamily, and 
cadherins, play major roles in mediating cell–cell interactions and therefore are 
candidates for receptors involved in capillary tube formation 
5
. Endothelial cells express 
both VE-(vascular endothelial) and N-(neuronal) cadherins. Whereas VE-cadherin is 
localised at sites of cell-cell contact, N-cadherin is distributed diffusely over the cell 
surface and does not seem to contribute to cell-cell adhesion 
6
. 
VE-cadherin and N-cadherin have been shown to participate in capillary tube formation. 
In particular, antibodies directed against VE-cadherin, but not against N-cadherin, 
PECAM-1 (Ig superfamily) or αvβ3 integrin, markedly inhibited the generation of 
capillary tubes 
7, 8
. Moreover, it has been demonstrated that blocking VE-cadherin 
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function leads to a marked reorganisation of the actin cytoskeleton, increased monolayer 
permeability and enhanced neutrophil transmigration 
7, 9
. 
Phlebotonics are known as venoactive drugs, whose mechanism of action is not well 
established despite the availability of numerous studies concerning their 
pharmacological and clinical properties. Phlebotonics may have beneficial effects on 
oedema and on some signs and symptoms related to CVI such as trophic disorders, 
cramps, restless legs, swelling and paraesthesia when compared with placebo 
10
. 
Aminaphtone (C18H15NO4, AMNA), a naphtohydrochinone used in the treatment of 
capillary disorders, has been reported to be effective in reducing vessel permeability and 
the healing of leg ulcers in patients with CVI and other pathological conditions 
11, 12
. 
In particular, in patients with idiopathic cyclic oedema syndrome, a clinical 
conditions that exhibits a vascular capillary hyperpermeability accompanied by 
oedema caused by the interstitial retention of fluid, a significant reduction in limb 
size was obtained after treatment with AMNA (P<0.0001) 
12
. AMNA acts on 
venous, capillary and lymphatic levels, reducing hyperpermeability, increasing 
venous resistance, and regulating lymphatic flux. This mechanisms of action result 
in reduced venous stasis, improved venous return, and, therefore, inducing tissues 
protection against toxins and free radicals, as demonstrated in a work of De Anna 
et al. in patients with chronic venous and lymphatic stasis 
11
. Finally, the use of 
AMNA was associated with significant improvements in quality of life compared 
with placebo in CVI patients 
13
. 
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Aim of the present study is to investigate the effect of AMNA on in vitro model of 
vascular endothelial permeability and to evaluate if the drug is able to stabilise 
capillary-like structures formed by HUVECs in an extracellular matrix model. 
 
2. Materials and methods 
 
2.1. Aminaphtone 
AMNA was generously gifted by Baldacci Spa, Pisa, Italy. Lyophilised AMNA 0.1 g 
was diluted with dimethyl sulphoxide to obtain a 100 mg/ml concentration. The solution 
was then diluted with Medium 199 (Lonza, Basel, Switzerland) supplemented with 1 % 
foetal bovine serum (FBS; Hyclone, South Logan, UT, USA), penicillin/streptomycin, 
HEPES (Lonza, Basel, Switzerland), glutamine (Sigma-Aldrich 3050 Spruce St., St. 
Louis, Missouri 63103 United States), heparin (Epsoclar) and bovine retina-derived 
extract as a complete growth medium. 
 
2.2. Cell isolation and culture 
HUVECs were isolated from fresh human umbilical cords by incubation with 
collagenase, (Invitrogen, Auckland, New Zealand) and cultured on gelatine-coated 
flasks in Medium199 (Lonza) containing 20% heat-inactivated FBS (Hyclone), sodium 
heparin (Epsoclar), penicillin/streptomycin (Lonza), HEPES (Lonza), glutamine 
(Sigma-Aldrich 3050 Spruce St., St. Louis, Missouri 63103 United States) and bovine  
retina-derived  extract in humidified atmosphere (37 °C, 5% CO2). The P4–P5 cultures 
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were cultivated until sub-confluence was reached. Thereafter, HUVECs were exposed 
to the different experimental conditions. 
 
2.3. Cell viability  
HUVECs, 3x10
4
 cells/well, were seeded in 96-well plates in complete growth medium. 
After 72 h, cells were washed with PBS and treated for 6 h with different concentrations 
of AMNA (0 – 1 – 5 – 10 – 30 – 50 – 70 – 100 µg/ml) in growth medium containing 1% 
FBS. After treatment, cells were washed twice with phosphate buffer saline (PBS) and 
viability was evaluated by WST-1 assay. WST-1 assay is a colorimetric assay based on 
the cleavage of tetrazolium salt (WST-1, 4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolium]-1,3-benzene disulphonate, Roche Applied Science, Mannheim, Germany) 
by mitochondrial dehydrogenases in viable cells. Briefly, after treatment, HUVECs 
were incubated with tetrazolium salt (10 µl/well) for 4 h at 37 °C, 5% CO2. Then, the 
formazan dye formed was quantified by measuring the optical density at 450 nm 
(reference wavelength: 650 nm), by a multiplate reader (Titertek). The absorbance 
directly correlated to the number of metabolically active cells. Viability was expressed 
as percent of viable cells, calculated from the ratio of absorbance after treatment to 
mean absorbance for the untreated control. 
 
2.4. Vascular permeability assay 
Vascular permeability was performed by Millipore assay kit (EMD Millipore 
Corporation Division Headquarters, Massachusetts, USA) according to the manufacture 
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protocol. Briefly, 80% confluent HUVECs, were detached and plated on inserts (3 x 10
4 
cells/insert) and incubated for 72 h at 37 °C, 5% CO2, up to form a monolayer. Cells 
were then washed and treated with different concentrations of AMNA (0.5-1-5-10-20 
µg/ml) for 6 h with or without 50 ng/ml VEGF (Recombinant Human VEGF165, 
Peprotech EC Ltd, London, UK) for 2 h, in growth medium with 1% FBS. At the end of 
incubation, all treatments were removed and an high molecular weight fluorescein 
isothiocyanate-dextran (FITC-dextran, MW 70KDa) was used to evaluate permeability. 
Plate was incubated in the dark for 20 min at room temperature. Permeation was 
arrested by removing the inserts from the wells. The levels of FITC-dextran was 
recorded by a sensitive fluorescence plate reader (Fluoroskan, Thermo Fisher ®), (Ex: 
485 nm; Em: 538). The amount of diffused dextran has determined using calibration 
curves established just with the stock solution. 
 
2.5. Western blot analysis of  VE-cadherin  
To determine VE-cadherin and VE-cadherin phosphorylation expression, HUVECs 
were seeded in appropriated density in 6 multiwells and cultured in complete growth 
medium until confluence. Cells were afterwards washed and pre-treated with 10 µg/ml 
AMNA for 6 h and then with 50 ng/ml VEGF for 2 h in medium with 1 % FBS. At the 
end of each treatment cells were lysed at 4°C for 1 h in lysis buffer (50 mM Tris–HCl 
pH 7.4, 150 mM NaCl, 1 mM PMSF, 1mM EDTA, 5 mg/ml Aprotinin, 5 mg/ml 
Leupeptin, 1% Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS) and centrifuged at 
10,000 X g for 15 min. The protein content of the supernatants was measured by 
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Bradford method. Aliquots containing 50 mg of cell lysate proteins were subjected to 
7.5% SDS-PAGE under reducing conditions and blotted onto nitrocellulose membrane 
filters. The blots were blocked for 2 h at 37 8C in 2% BSA, 1mM Na2HPO4, 1.7mM 
NaH2PO4, 150mM NaCl, 0.05 Tween-20 (PBS-T). The nitrocellulose membranes were 
washed once with PBS-T for 15 min, three times for 5 min with 1mM PBS and 
immunoblotted for 2 h at room temperature with rabbit polyclonal anti-VE Cadherin 
(phospho Y685) antibody (Abcam Ltd) or with rabbit monoclonal anti-VE-cadherin 
antibody (Cell Signaling Technology, Boston, USA). After one washing with PBS-T 
and three washing with PBS, the blots were incubated for 1 h at room temperature with 
HRP labelled anti-rabbit IgG, washed with PBS, developed for 2 min with ECL reagent 
(Pierce) and exposed to Biomax film (Kodak Co.). The densitometry data of the protein 
bands were obtained using ImageJ software, and the objective protein expression was 
evaluated by the densitometry ratio of the objective proteins to β-actin. 
 
2.6. Immunofluorescent detection of VE-cadherin 
The distribution of VE-cadherin in HUVEC monolayers was assessed by 
immunofluorescent techniques using previously described procedure 
14
 with 
modifications. Cells were placed on multiwell slides. Confluent cultures of HUVECs 
were pre-treated with AMNA (10 µg/ml) for 6 h and with VEGF (50 ng/ml) for 2 h in 
medium with 1 % FBS. At the end of treatment, cells were washed three times with 
PBS containing 1 mM CaCl2 and 1 mM MgCl2 (DPBS) and then fixed with 4% 
formaldehyde at room temperature for 15 min. The formaldehyde was then aspirated 
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and the cells were washed three times with DPBS. The washed cells were then 
permeabilised with 0.5% Triton X-100 for 5 min at room temperature. Non-specific 
binding sites were blocked by incubation with 3% BSA in DPBS for 5 min at room 
temperature. The BSA was then aspirated and the cells were immediately incubated 
with primary mouse monoclonal antibodies against human VE-cadherin (10 mg/ml in 
DPBS) (Cell Signaling Technology, Boston, USA) for 1 to 12 h at 37°C in a humidified 
chamber. At the end of incubation the primary antibody were removed, cells were 
washed three times and incubated at 37°C for 30 min with FITC- conjugated anti-mouse 
secondary antibody (Cell Signaling Technology) diluted 1:200 and rhodamine-
phalloidin for F-actin staining (Cytoskeleton, Inc.) diluted 1:400 in DPBS. The chamber 
slides were then washed and mounted with Vectashield mounting medium containing 
DAPI (Vector Laboratories, UK). Slides were viewed under a fluorescence microscope 
(Nikon) equipped with a digital CCD camera and 20X objective. Images were recorded 
using AxioVision (Carl Zeiss MicroImaging, GmbH) software. 
 
2.7. In vitro capillary tube maintenance  
To evaluate the capability of AMNA to maintain capillary tubes formation, HUVECs 
were treated with 10 µg/ml AMNA for 6h and then 7x10
4
 cells/well were plated on 
Matrigel (BD Biosciences) for 48 h. Matrigel was thawed on ice at 4 °C and used to 
coat 24-well plates for 30 min at 37 °C. Cells were monitored and optical microscopy 
images were captured at 2, 8, 24 and 48 h. Five independent images were taken for each 
well.  
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To quantify angiogenic structures formed by HUVECs, computational morphometric 
analysis was performed 
10
. Briefly, representative fields from each experimental setting 
were taken. Number of meshes (number of closed meshes) and master segment length 
(total length of the network) of capillary tubes, in five random fields for each sample 
and time of acquisition, were calculated using Angiogenesis Analyzer for ImageJ 
software 
13
. Results for different experimental groups were expressed as mean ± SD 
from three independent experiments. Representative pictures at higher magnification 
were also taken. 
 
2.8. Statistical analysis  
Data are presented as mean ± SD of independent experiments. Comparisons were made 
using Student’s t-test or by ANOVA when appropriate. Values of P<0.05 were 
considered statistically significant. Statistical analysis was carried out using the Graph-
Pad Prism 5 software (GraphPad Software, Inc., La Jolla, CA 92037 USA). 
 
3. Results 
 
3.1. Effect of Aminaphtone on cell viability 
To determine non-toxic concentration of AMNA, HUVECs were incubated in the 
presence of different concentrations of drug (1–100 µg/ml). Dose-dependent HUVEC 
viability indicated that no significant cytotoxic effects were observed at AMNA 
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concentrations below 30 µg/ml. At concentration up to 30 µg/ml there was a rapid 
reduction in cell viability, Figure 1. 
 
3.2. Effect of Aminaphtone on endothelial cell permeability 
The effect of different concentrations of AMNA on VEGF-induced HUVEC 
permeability has been shown in figure 2. VEGF-induced cell permeability was 
significantly reduced at a range concentration of 1-20 µg/ml AMNA (P<0.05 vs VEGF), 
restoring normal condition. AMNA alone not affect cell permeability. 
 
3.3. VE-cadherin fluorescent detection 
To evaluate the effect of AMNA on VE-cadherin localisation, cells were fixed and 
processed for immunofluorescence (Figure 3) As showed in figure, VE-cadherin was 
localized as bright intense immunostaining at all cell–cell contacts (control and AMNA 
treatment). VEGF stimulation for 2 h reduced the staining of VE-cadherin at cell–cell 
contacts, that was now expressed in an irregular manner, and a loss of cell–cell 
adhesions. On the contrary, AMNA pre-treatment restored VE-cadherin staining at cell-
cell contacts that was distributed in a striped fashion, like controls.  
 
3.4. VE-cadherin expression 
To correlate the immunolocalization changes with protein expression, Western blot 
analysis of total VE-cadherin and phospho-VE-cadherin were performed (Figure 4). 
Immunoblotting demonstrated that the levels of total VE-cadherin remained the same in 
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all treatment conditions. However, phosphoY685-VE-cadherin resulted reduced by 
AMNA pre-treatment (P<0.005 vs VEGF) and increased by VEGF treatment (P<0.001 
vs control), as confirmed by densitometry analysis. These data suggest a potential 
protective role of AMNA on VE-cadherin degradation induced by VEGF. 
 
3.5. In vitro capillary tube maintenance   
HUVECs, when seeded on Matrigel, formed capillary-like structures. This process has a 
rapid onset, beginning within 1 h and is completed by 8-12 h; after this time the network 
starts to rearrange and completely disappears within 24-48 h. 
Figure 5 shows the effect of 10 µg/ml AMNA 6h pre-treatment on capillary-like 
structure maintenance, formed by HUVECs. In figure 5 A, AMNA significantly 
reduced degradation of endothelial cells organised in endothelial cell cords on Matrigel 
at 24 h and 48 h compared with control. Figure 5 B, shows the number of meshes and 
master segment length of capillary tubes formed by HUVECs. After 48 h, there was a 
significant difference in number of meshes and master segment length between control 
and AMNA-treated cells (P<0.01). 
 
4. Discussion 
CVI is characterised by venous hypertension associated with decrease in 
microcirculatory blood flow and increase in post-capillary permeability of the veins, 
leading to oedema of the legs and feet 
15
. The most used phlebotropic drugs, or oedema-
protecting drugs, are the gamma-benzopyrone family (flavonoids) 
16
. Results of clinical 
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studies show that flavonoids decrease capillary permeability and increase capillary 
resistance, which could partly be explained by inhibition of leukocyte activation, 
migration, and adhesion 
16, 17
. As reported by Ramelet et al. (2000), this inhibition is 
linked to a significant decrease in plasma levels of endothelial adhesion molecules 
(VCAM-1 and ICAM-1) after flavonoids treatment 
18
. Beside the clinical outcome in 
patients with CVI, AMNA has shown interesting endothelial-protective properties, 
inducing down-regulation of sELAM-1 and sVCAM-1 in patients with systemic 
sclerosis 
19
. Moreover, AMNA is a molecule with a demonstrated anti-endothelin1 (ET-
1) effect in vitro, interfering with the transcription of the pre-pro-ET-1 (PPET-1) gene 
20
. Furthermore, ET-1 is known to acts as a permeability factor in the vascular 
endothelium 
21-23
. It is known that HUVECs treated with VEGF increased their ET-1 
production in a concentration and time-dependent manner 
24
. In addition, Chen et al. 
(2000), demonstrated that VEGF increased both ET-1 mRNA and ET-1 protein 
expression along with endothelial cell permeability in HUVECs cultured in normal 
glucose condition. Interestingly, they reported that ET-1 induces a disruption of the 
endothelial cell junctions 
25
. Moreover, in a recent work, we demonstrated that AMNA 
reduced significantly ET-1 secretion in HUVECs 
26
. 
 In this  study, AMNA was able to restore vascular permeability induced by VEGF in a 
concentration range of 1-20 µg/ml. Inhibition of VE-cadherin function induces a 
reorganisation of the actin cytoskeleton leading to a loss of junctional VE-cadherin 
localization, reduces cell-cell adhesion and increases permeability 
27
. It is know that 
VEGF stimulation reduces VE-cadherin staining at the adherent junction 
7, 27-29
. 
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Moreover, it is generally accepted that the tyrosine phosphorylation of VE-cadherin is 
associated with weak junctions and impaired barrier function. In particular, it has been 
proved that VEGF enhance the permeability of HUVEC monolayers and increase 
tyrosine phosphorylation of VE-cadherin 
30
. In our study, AMNA pre-treatment restored 
VE-cadherin localization at the cell-cell contacts. In addition, protein expression of total 
VE-cadherin remained the same in all treatment conditions, whereas  phospho-tyrosin 
685-VE-cadherin resulted increased by VEGF treatment (compared to control) and 
reduced by AMNA pre-treatment.   
Finally, HUVECs, when seeded on Matrigel, formed capillary-like structures. This 
process has a rapid onset, beginning within 1 h and is completed by 8-12 h; after this 
time the network starts to rearrange and completely disappears within 24-48 h. We used 
Matrigel assay to evaluate the effect of AMNA pre-treatment on degradation time of 
capillary-like structures formed by HUVECs. In accordance with the role of VE-
cadherin in both formation and maintenance of capillary tubes in fibrin collagen gel-
over-gel assays 
7
, our data showed that AMNA improved stability of endothelial cells 
organised in capillary-like structures, as observed after 48 h.  
 
4.1. Limitations and future directions 
One potential limitation of this study was the completely absences of  in vitro studies on 
the mechanism of action of AMNA and its intracellular pathway involved. Here, for the 
first time, the influence of AMNA on VE-cadherin modulation was suggested. 
Moreover, we lack of clinical experience of oedema reduction. 
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Future direction may be an in vitro study on endothelial cells cultured from veins of 
patients with CVI to set up a personalized study. Finally, a multicentric clinical studies 
would be essential to confirm the effect of AMNA on oedema reduction mainly in leg 
ulcer. 
 
4.2. Conclusion 
AMNA is used to reduce lower limbs oedema in chronic venous insufficiency.  
On the basis of our experience, we can suppose that the effect of AMNA is due to 
protection of VE-cadherin degradation induced by VEGF and to its effect on ET-1 
expression. These properties of AMNA may also explain the stability of endothelial 
cells organised in extracellular matrix.  
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Figure 1. Dose-dependent effect of AMNA on cell viability. HUVECs were treated with different concentration 
of AMNA (1 – 5 – 10 – 30 – 50 – 70 – 100 µg/ml) for 6 h. Cell viability was evaluated by WST-1 colorimetric 
assay (Abs 450 nm). Data are expressed as percentage of control of 3 independent experiments ± SD.  
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Figure 2. Permeability of HUVEC monolayers to FITC-dextran. Cells were grown to confluency on Transwell 
filters and pre-treated with different concentrations of AMNA (0.5 – 1 – 5 – 10 – 20 µg/ml) for 6h and than 
with or without VEGF (50 ng/ml) for 2h. Permeability was measured using FITC-dextran (MW 70 KDa) as 
described in Materials and Methods. Data are expressed as percentage of  FITC-dextran diffusion of  empty 
filter (no cells) and are representative of three independent experiments. Ex 485 nm; Em 538 nm. **P < 
0.05 vs VEGF.  
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Figure 3. VE-cadherin localization in HUVECs. Confluent cell monolayers were pre-treated with AMNA (10 
µg/ml) for 6 h and with VEGF (50 ng/ml) for 2 h. Cells were immunostained for VE-cadherin (green) and F-
actin (red). Cell nuclei were counterstained with DAPI (blue). All fluorescence images were taken at five 
different fields/well, and images are representative of three independent experiments (magnification 20X).  
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Figure 4. VE-cadherin expression. HUVECs  were cultured until confluences and pre-treated with 10 µg/ml 
AMNA for 6 h and then with 50 ng/ml VEGF for 2 h in medium with 1 % FBS.  Western blot analysis of cell 
lysate was performed. Anti-VE Cadherin (phospho-Y685) at 140 kDa and anti-VE-cadherin antibody at 147 
kDa were detected. Quantitative analysis has been normalized to beta-actin (as control). Samples derive 
from the same experiment and the gels and blots were processed in parallel. **P<0.005 vs VEGF and § 
P<0.001 vs control.  
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Figure 5. Capillary-like structures maintenance. Cells were treated for 6 h with 10 µg/ml AMNA and then 
7x104 cells/well were plated on Matrigel for 48 h. Images were acquired after 2-8-24-48 h. Images are 
representative of 5 random-field (original magnification 5X) (A). Optical microscope images were analysed 
through Angiogenesis Analyzer for ImageJ software to measure number of meshes and master segment 
length of capillary tubes formed by HUVECs after 2-8-24-48 h (B). Five random fields for each sample and 
time of acquisition were analysed. Values in the graph are the mean from three independent experiments ± 
SD. **P<0.01 vs control.  
 
137x99mm (300 x 300 DPI)  
 
 
Page 24 of 25Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Under Review
Declarations 
Competing interests: The Authors declares that there is no conflict of interest  
Funding: This research received no specific grant from any funding agency in the public, 
commercial, or not-for-profit sectors.  
Ethical approval: NA 
Guarantor: RD 
Contributorship: FF and RD  researched literature, wrote and conceived the study. EB was 
involved in protocol development, acquisition and analysis of data. TS and EI revised critically the 
manuscript for important intellectual content.  AF and RD approved the version to be published. All 
authors reviewed and edited the manuscript and approved the final version of the manuscript. 
Acknowledgements: NA 
 
Page 25 of 25 Phlebology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
